Hengrui Pharmaceutical announced that Beijing Shengdi Pharmaceutical, a subsidiary of the company, received a notice from the State Drug Administration to approve the marketing of the new class 1 drug refusibizumab injection independently developed by the company. This drug is used to treat homozygous familial hypercholesterolemia in adults and adolescents aged 12 and above to reduce LDL cholesterol levels. Up to now, this drug-related project has invested about 303 million yuan in R&D.

Zhitongcaijing · 4d ago
Hengrui Pharmaceutical announced that Beijing Shengdi Pharmaceutical, a subsidiary of the company, received a notice from the State Drug Administration to approve the marketing of the new class 1 drug refusibizumab injection independently developed by the company. This drug is used to treat homozygous familial hypercholesterolemia in adults and adolescents aged 12 and above to reduce LDL cholesterol levels. Up to now, this drug-related project has invested about 303 million yuan in R&D.